Verrica Pharmaceuticals Inc. (VRCA) Reports First Patient Enrollment in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts
Tweet Send to a Friend
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) today announced that the first patient has been enrolled in the company’s Phase 2 ‘CARE’ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
